Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Rhythm Pharmaceuticals Inc
RYTM | US
85.70
USD0.49
0.58%
RYTM | US
Loading StockChartView...
About Rhythm Pharmaceuticals Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
24/04/2026
Close
85.70
Open
85.10
High
86.39
Low
83.12
Rhythm Pharmaceuticals Inc. a commercial-stage biopharmaceutical company focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC) proprotein convertase subtilisin/kexin type 1 leptin receptor (LEPR) deficiency obesity and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide which is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities steroid receptor coactivator 1 deficiency obesity SH2B1 deficiency obesity MC4 receptor deficiency obesity and other MC4R disorders. The company was formerly known as Rhythm Metabolic Inc. and changed its name to Rhythm Pharmaceuticals Inc. in October 2015. Rhythm Pharmaceuticals Inc. was founded in 2008 and is headquartered in Boston Massachusetts.
View LessRYTM | US
Risk
56.6
Sharpe
0.67
Luna's Score
40/100
Recommendation
Sell
Luna says (RYTM | US)
What's Working
Strong Revenue Growth (> 10%)
What's not Working
Price Below SMA10D
Midcap (2B - 10B USD)
High Market Beta (> 0.8)
High Short percentage (> 15%)
High Debt to Equity (> 0.75)
High Debt to Asset (> 0.45)
Rich in Valuation (Price to Book > 8)
Weak Operating Margin (< 10%)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
Loading RiskMeterView...
10 days
25.3%1 month
56.6%3 months
50.0%6 months
50.7%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
79.29
Debt to equity
6.42
Debt to assets
0.66
Ent. to EBITDA
-12.65
Ent. to rev.
28.93
PEG
-
Other Fundamentals
EBITDA
-263.94M
MarketCap
5.24B
MarketCap(USD)
5.24B
Div. yield
-
Op. margin
-139.21
Erngs. growth
-
Rev. growth
51.30
Ret. on equity
-143.42
Short ratio
17.22
Short perc.
20.42
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
7.83
Range1M
16.29
Range3M
36.74
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
0.37
Price X volume
23.69M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -12.65 | 0.53 | Cheaper |
| Ent. to Revenue | 28.93 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 79.29 | 15.55 | Expensive |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 50.03 | 72.80 | Lower Risk |
| Debt to Equity | 6.42 | -1.23 | Expensive |
| Debt to Assets | 0.66 | 0.25 | Expensive |
| Market Cap | 5.24B | 3.66B | Market Leader |
